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Expression of DAPK1, a critical regulator of autophagy and
apoptosis, is lost in awide variety of tumors, although themech-
anisms are unclear. A transcription factor complex consisting of
ATF6 (an endoplasmic reticulum-resident factor) and C/EBP-
is required for the IFN--induced expression ofDAPK1. IFN--
induced proteolytic processing of ATF6 and phosphorylation of
C/EBP- are obligatory for the formation of this transcriptional
complex. We report that defects in this pathway fail to control
growth of chronic lymphocytic leukemia (CLL). Consistent with
these observations, IFN- and chemotherapeutics failed to acti-
vate autophagy in CLL patient samples lacking ATF6 and/or
C/EBP-. Together, these results identify a molecular basis for
the loss of DAPK1 expression in CLL.
Multiple genes are inactivated during the progression of a
normal cell into malignant one. The death-associated protein
kinase-1 (DAPK1) is a Ca2/calmodulin-dependent serine/
threonine kinase that controls several aspects of cell growth,
including cell cycle check points, apoptosis, and autophagy, and
suppresses tumor metastasis (1–3). Expression of DAPK1 is
frequently lost in a variety of solid and hematologic malignan-
cies, including chronic lymphocytic leukemia (CLL)2 (4). How-
ever, the precise molecular mechanisms of such loss are not
known. CLL, a mature B cell malignancy, is one of the more
prevalent types of adult leukemias. Limited therapeutic inter-
ventions are available for advanced stages, and, as a result,
increased mortality of elderly patients occurs (5). A major pro-
portion ofCLLpatients display abnormalities in cytokine secre-
tion and/or response (6). For example, phytohemagglutinin-
activated CD2 cells fromCLL patients produced higher levels
of IFN- andTNF- comparedwith healthy individuals. Serum
IL2 and IL4 levels were significantly higher inCLLpatients than
in the healthy controls (7).
IFNs promote cell cycle arrest, apoptosis, and autophagy by
inducing a number of cellular genes (8, 9). The well described
IFN-induced JAK-STAT pathways are critical for executing
acute responses, such as antiviral activities. However, a number
of other pathways regulate IFN-induced chronic biological
activities, such as cell growth and adaptive immunity. Earlier,
we identified a non-STAT pathway in which transcriptional
factor CCAAT/enhancer-binding protein- (C/EBP-) pro-
motes IFN-induced responses (10, 11). C/EBP- is critical for
the IFN-induced expression of DAPK1 (12–14). Importantly,
C/EBP- cooperates with the activating transcription factor 6
(ATF6), a key ER stress-associated transcription factor, for
inducingDAPK1 expression in response to IFN- (15).Wehave
shown that the IFN-induced threonine phosphorylation of
C/EBP- in its second regulatory domain by ERK1/2, along
with the phosphorylation and proteolytic activation of ATF6, is
obligatory for DAPK1 expression (15, 16). Because most of
these studies were restricted to mouse embryonic fibroblasts
(MEFs), the relevance of this new pathway to human cancers is
not clear. Here we examined the importance of this pathway to
cell growth control via autophagy using a CLL model.
Autophagy, an intracellular vesicle-initiated, lysosome-de-
pendent self-digestion, is emerging as a major mechanism for
tumor suppression, pathogen elimination, removal of apoptotic
cells, and antigen presentation (17). Autophagy appears to play
a dual role in cancer cells. It promotes cancer cell survival by
supplying energy sources. In contrast, it serves as an effective
tumor-suppressive mechanism due to excessive digestion of
cellular contents (18).
Although onemajormechanism forDAPK1 silencing in can-
cer appears to be promoter methylation, it is often silenced
without apparent methylation in many cases (19). Mutational
inactivation of DAPK1 is uncommon, except in the case of a
familial form of CLL that diminishes its expression (20). In one
case, this rare “CLL haplotype” resulted in an increased binding
of the homeobox transcription factor HOXB7 to the DAPK1
promoter, resulting in a slight but significant reduction of its
expression (20). This aberration is not global to all CLLs. Thus,
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there is a critical need to understand how DAPK1 expression
is suppressed. We hypothesized that a dysfunction in the
C/EBP- and ATF6 pathway contributes to a loss of DAPK1
expression and growth control in CLL. We report here that




sion Levels in B Cells—We first investigated whether DAPK1
expression was induced by IFN- in B cell tumor line MEC1
(derived from a case of CLL) and compared it with a control B
cell line.Western blotting analyses showedhigher basalDAPK1
levels in the B cell line, which was further stimulated following
IFN- treatment (Fig. 1A). Neither basal nor IFN-induced
expression of DAPK1was detected inMEC1. Similarly,DAPK1
mRNA was induced following IFN- treatment, only in the
control B cell line and not inMEC1 (Fig. 1B). Notably, even the
basal DAPK1mRNA expression was significantly lower in this
tumor line, compared with the control. Because DAPK1 partic-
ipates in autophagy and tumor suppression, such a defect could
result in an inhibition of autophagy. Initially, we examined the
levels of Beclin1 (BECN1), a crucial regulator of autophagy and
tumor suppression (Fig. 1B). No significant differences were
observed in the basal and IFN-induced BECN1mRNA levels in
the control B cell line andMEC1.Next, we investigatedwhether
IFN- differentially stimulated autophagy in these cells bymea-
suring the formation of LC3 puncta. IFN- induced significant
LC3 puncta only in the control B cell line and not in the MEC1
cell line (Fig. 1C).
Alternatively, LC3-II formation, p62 (SQSTM1) degrada-
tion, and Beclin1 (Thr119) phosphorylation levels were mea-
sured in these cells using Western blotting analyses with spe-
cific antibodies (Fig. 1D) to confirm activation of autophagy.
The increase in formation of LC3-II correlatedwell with puncta
formation in the control B cell line. The p62 (SQSTM1) protein
cargoes oxidized protein aggregates to autophagosomes (21),
which are degraded along with the cargo during autophagy.
Thus, higher cellular p62 levels indicate a defect in autophagy.
Upon IFN- treatment, p62 was lowered only in the control B
cell line andnot inMEC1 (Fig. 1D). BecauseDAPK1 is known to
phosphorylate Beclin1 during autophagy (22), we next exam-
ined its phosphorylation at Thr119. Although both cell lines
expressed comparable levels of total Beclin, increased Beclin1-
Thr(P)119 was found only in the control B cell line and not in
MEC1 in response to IFN treatment (Fig. 1D). To ensure the
critical role of DAPK1 in autophagy, we investigated whether a
knockdown ofDAPK1 using RNAi in the control B cell line and
an introduction of DAPK1 into MEC1 would alter autophagy.
Fig. 1E shows theWestern blotting analysis of DAPK1 levels in
these cell lines along with their corresponding controls. Immu-
nofluorescence analyses showed that DAPK1 depletion in the
control B cell line caused a significant loss of the IFN--induced
LC3 puncta when compared with the scrambled shRNA con-
trol (Sc shRNA) (Fig. 1F). In contrast, DAPK1 expression in
MEC1 yielded maximum LC3 puncta, compared with vector
control, following IFN- treatment.
DAPK1 Expression in B Cell Lines Requires ATF6 and
C/EBP-—Because our recent studies using MEFs identified a
major role for ATF6 and C/EBP- in promoting DAPK1
expression, we investigated the relevance of these transcription
factors (Fig. 2A) to DAPK1 expression in B cells, using RNAi.
The ATF6- or C/EBP-- specific shRNAs, but not the scram-
bled shRNA control, suppressed the IFN-induced expression of
DAPK1 in B cells (Fig. 2B). Because the levels of the targeted
proteins were not significantly different between mock-trans-
fected and scrambled shRNA control-transfected cells (Fig.
2A), in the following experiments, all comparisons were made
between scrambled shRNA control and specific shRNA trans-
fectants. Immunofluorescence analyses showed that only B
cells with scrambled shRNA control yielded maximum num-
bers of LC3 puncta upon IFN- treatment, when compared
with either ATF6 orC/EBP- depletion, signifying their impor-
tance in IFN-induced autophagy (Fig. 2C). Notably, we were
able to co-localize LC3 puncta and DAPK1 in the IFN-treated
control cells but not in ATF6- or C/EBP--depleted cells.
Because certain histone deacetylases (HDACs), HDAC2 and
HDAC5, were known to repress DAPK1 in certain forms of
acutemyeloid leukemia (23), wemeasured their levels byWest-
ern blotting analysis and found that such differences were not
due to an increased expression of HDACs in these cells when
either ATF6 or C/EBP- was depleted (Fig. 2B). To address
whether theATF6C/EBP- complex is recruited to theDAPK1
promoter upon IFN- treatment, we performed ChIP assays
with specific antibodies. DAPK1 promoter-specific PCR prod-
ucts were observed only in the control B cell line and not in
MEC1 following IFN- treatment (Fig. 2D). The control reac-
tions with either no IgG or non-reactive rabbit IgG (NR-IgG)
yielded no products, showing the specificity of the ChIP assay.
Real-time quantitative PCR (qPCR) analysis of these ChIP
products is shown in Fig. 2E. Thus, a failure to recruit ATF6
and/or C/EBP- to theDAPK1 promoter may result in a loss of
DAPK1 expression in the tumor cells.
We next examined the mechanistic bases for the lack of
ATF6 and C/EBP- recruitment to the DAPK1 promoter in
MEC1 cells. Because IFN-induced phosphorylation ofC/EBP-
and proteolytic activation of ATF6 are required for DAPK1
expression, we checked whether any aberrations in these pro-
cesses were responsible for the lack of transcription factor
recruitment to the DAPK1 promoter. Only the control B cells
showed higher levels of phospho-Thr235 C/EBP- (a known
ERK-phosphorylated site) and activated ATF6 (50-kDa form)
upon IFN- treatment (Fig. 2F). Strikingly, phospho-Thr235
C/EBP- was barely detectable in MEC1 cells, whereas normal
proteolytic activation of ATF6 was detected in MEC1 tumor
cells upon IFN- treatment. Bar graphs in the bottom panel of
Fig. 2F show the quantified data.
The importance of previously reported ERK and p38 MAPK
signaling pathways for IFN--induced C/EBP-ATF-6-depen-
dent DAPK1 expression was examined in B cell lines by using
chemical inhibitors.We used PD98059 and SB20219 for specif-
ically blocking the activation of ERK1/2 and p38 MAPK,
respectively. An unrelated inhibitor that blocks the PI3K path-
way was used as a control. The effects of these inhibitors on the
DAPK1 mRNA levels in B cells and MEC1 tumor cells were
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studied. Only PD98059 and SB20219 and not the control inhib-
itor LY294002 or DMSO blocked the IFN-induced DAPK1
mRNA levels in B cells (Fig. 2G). However, in MEC1 cells, as
predicted, IFN- treatment did not yield any significant differ-
ences in the presence or absence of specific inhibitors. In the
next experiment, we investigated whether the ATF6C/EBP-
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complex is recruited to theDAPK1 promoter upon IFN- treat-
ment in the presence of these inhibitors. We performed ChIP
assays with specific antibodies. qPCR analyses of the ChIP
products are shown in Fig. 2H. Only the specific inhibitors
PD98059 and SB20219 and not the DMSO control blocked the
IFN-induced recruitment of ATF6 and C/EBP- to theDAPK1
promoter.
Loss of DAPK1 Expression Correlates with That of ATF6/
CEBPB in CLL—To examine the clinical relevance of the above
observations, we investigated whether a correlation exists
between DAPK1 levels and ATF6 or C/EBP- expression in
primary CLL. The patient sample details are shown in Table 1.
Because we could only obtain small quantities of purified pri-
mary tumor cells, we measured expression levels of the stated
mRNA by qPCR. Peripheral blood lymphocytes (PBLs) from
healthy individuals (n  8) were used as a control in these
experiments. qPCRanalyses of the steady state levels ofDAPK1,
ATF6, BECN1, and CEBPB mRNAs in the patient samples
showed a loss of their expression in the majority of CLLs (Fig.
3A). Unlike in the MEC1 tumor cell line, many CLL samples
also expressed a significantly lower level of BECN1 when com-
pared with the controls.
Because ATF6 is also involved in ER stress responses, we
investigated changes in the mRNA levels of ER stress response
genes, such asHSPA5 (BiP),ATF4, andXBP1. BothHSPA5 and
ATF4 levels were significantly low in many samples. No signif-
icant changes in XBP1 levels were observed in these samples
(Fig. 3B). We also investigated whether there were any differ-
ences in mRNA levels of IFN-induced tumor suppressor genes
IRF1 and IRF8 (24, 25). These transcripts were abundantly
expressed in CLL samples, and their levels were comparable
with those of healthy controls (Fig. 3B).
Fig. 3C shows the relative abundance of DAPK1, ATF6, and
CEBPB mRNAs in each CLL sample. Although two samples
(patients A and J) expressed normal levels ofCEBPB, they had a
lower level of ATF6. In another sample (patient C), ATF6 and
CEBPBmRNA levels were similar and lower, respectively, com-
pared with controls. Thus, low DAPK1 levels correlated with
severely reduced expression of either ATF6 or CEBPB (except
for one from patient B).
To address whether the ATF6C/EBP- complex is recruited
to the DAPK1 promoter upon IFN- treatment in the patient
samples, we performed ChIP assays with specific antibodies.
DAPK1 promoter-specific PCR products were observed only in
the control PBL andnot in the patient samples (n 5) following
IFN- treatment (Fig. 3D).
ATF6 and C/EBP- Are Essential for Driving IFN-induced
DAPK1-dependent Autophagy in CLL—Because ATF6 and
C/EBP- are required for IFN- stimulated DAPK1 expression
and autophagy, we next checked the expression levels of these
proteins by immunofluorescence in different CLL patient sam-
ples. Fig. 4A shows the representative images for the levels of
DAPK1, C/EBP-, and ATF6 from CLL samples (different
patient samples) alongside a healthy control. After immuno-
staining with specific antibodies, images were captured, and
mean fluorescence intensity of the signals was determined
using ImageJ (National Institutes of Health). As observed in
qPCR profiles, DAPK1, ATF6, and C/EBP- levels were very
low in CLL patient samples when compared with healthy con-
trols. In some samples (B, F, and J), for which sufficient cell
numbers were available, we quantified DAPK1 levels using
Western blotting analyses (Fig. 4B). CLL samples F and J did not
express DAPK1. In patient sample B, where a high level of
steady state DAPK1 was observed, IFN- treatment did not
induce DAPK1 levels further. As expected, normal PBL con-
trol(s) expressed both steady state and IFN--induced DAPK1
(Fig. 4B).
In the subsequent experiments, we investigated the effects of
flavopiridol, a pan-cyclin-dependent kinase (CDK) inhibitor
(26), and chlorambucil, an alkylating agent (27), which demon-
strated significant clinical activity inCLL (28, 29), on autophagy
and cell growth. Fig. 4C (top panels) shows Western blotting
analyses of LC3-II p62, phospho-Beclin1, and Beclin1 levels in
the indicated CLL samples after IFN- (for 8 h), flavopiridol (2
M for 4 h), and chlorambucil (20 M for 4 h) treatments.
LC3-II formation was severely suppressed in the three CLL
samples compared with healthy control PBL. p62 levels were
either greater than or the same relative to the untreated control,
consistent with the ablation of autophagy in the CLL samples.
Consistent with these observations, phospho-Beclin1 levels
were also undetectable in all CLL samples when comparedwith
the control PBL. Fig. 4C (bottom) shows the quantified data for
each of the proteins analyzed. Thus, a loss of expression of
ATF6 and/or C/EBP- results in severely reduced autophagy in
CLL.
BecauseDAPK1 is a regulator of cell death, we alsomeasured
the percentage of viable cells in the tumor and control B cell
lines following treatment with IFN-, flavopiridol, and
chlorambucil (Fig. 4D). Upon IFN- treatment (for 4 or 16 h),
the percentage of viable cells significantly declined in the con-
trol B cell line but not in MEC1. Similarly, flavopiridol and
chlorambucil treatment significantly suppressed the viability of
the control B cell line but not MEC1. In summary, the tumor
cell lineMEC1 defective for C/EBP- phosphorylation (see Fig.
2) showed a poorer response to IFN- and therapeutic agents. A
similar experiment could not be performed in primary CLL
samples due to the limited availability of cells.
FIGURE1.Lossof IFN--stimulatedautophagyandDAPK1expression inMEC1, aBcell CLL cell line, comparedwithacontrolnon-oncogenicBcell line.
A, Western blotting analyses of cell lysates with the indicated antibodies. Cell types and time points of treatment (IFN-, 500 units/ml) are indicated. B, qPCR
analyses of DAPK1 and BECN1 transcripts. Cells were treated with IFN- for 12 h. n 5/sample. C, top panels, immunofluorescence signals of LC3 (FITC; green
channel). The nucleus is stained with DAPI (blue channel). Scale bar, 10 m. Bottom panel, quantified relative mean puncta after background correction. Bars,
mean S.D. (error bars) (n 3, 10 independent fields/sample). Relative levelswere calculatedwith respect to those obtainedwith the untreated control.D, top
panels, Western blotting analyses of lysates with the specific antibodies. Specific cells and treatments (IFN- for 12 h) are indicated. Bottom, histograms show
relative intensities of the bands after normalization to its actin internal control. E, Western blotting analyses of lysates from the indicated cell lines. Specific
genes transfected are also indicated. F, immunofluorescence signals of DAPK1 (FITC, green channel) and LC3 (Alexa Fluor 568, red channel). The nucleus is
stainedwithDAPI (blue channel). Scale bar, 10m. Treatmentwaswith IFN- for 12 h. Typical images and quantifiedmean puncta after background correction
are shown. Bars, mean S.D. (n 3; 10 independent fields/sample).
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Restoration of C/EBP- and ATF6 into CLL Patient Samples
Reestablishes IFN--induced DAPK1 Expression and Auto-
phagy—We next examined whether restoration of C/EBP-
and/or ATF6 in the defective CLL patient samples would rees-
tablish DAPK1 expression and autophagy. For this experiment,
wehave chosen twoCLLpatient samples: 1) sample Fwith a low
C/EBP- but a normal ATF6 level and 2) sample J with low
ATF6 but a normal C/EBP- level. These cells were transfected
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with lentiviral expression vectors encoding either C/EBP- (F)
or ATF6 (J) or control vector alone (F and J) (Fig. 5A). These
cells were examined for IFN-induced expression of DAPK1 and
autophagy. IFN- was able to induce DAPK1 expression and
promote autophagy (Fig. 5, B and C) only after a re-expression
of C/EBP- or ATF6 in these CLL samples.
Discussion
Autophagy maintains cellular hygiene by eliminating dam-
aged organelle or protein aggregates via sequestration into dou-
ble membrane intracellular vesicles and their subsequent
fusion with lysosomes. Autophagy has been linked to both sur-
vival and death (30), depending on the cell type, signal, and
physiologic state of a cell (31). For example, autophagy pro-
motes cell survival by providing nutrients during cell starvation.
In contrast, it can promote cell death via excessive digestion
organelles if cells fail to return to normal functions. Autophagy
promotes senescence to suppress tumor growth (32–34).
Blockade of autophagy enhances the apoptotic cell death mode
in some cases. Indeed, a number of regulators of autophagy also
participate in apoptosis (35). DAPK1 is one of the first known
proteins that directly connects autophagy to cell death through
phosphorylation of Beclin1, a known tumor suppressor (36).
DAPK1 employs several substrates for exerting its biological
effects (37). For example, it phosphorylates and activates pro-
tein kinase D, a tumor suppressor that regulates trans-Golgi
trafficking. During oxidative stress, DAPK1 binds and phos-
phorylates Vps34, a major regulator of autophagy (38). Impor-
tantly, DAPK1 phosphorylates Beclin1 at Thr119 to promote its
dissociation from Bcl-XL and induction of cell death via
autophagy (36). Consistent with its tumor-suppressive effects,
DAPK1 expression is lost in a variety of cancers, including CLL
(4). Overexpression of DAPK1 in the absence of p53 resulted in
autophagic cell death in some hepatoma cell lines (2). In estro-
gen receptor-negative breast tumors with wild-type p53,
DAPK1 serves as a death inducer. In contrast, in the p53mutant
background, DAPK1 functions as a growth promoter (39),
although the precise mechanisms are unclear at this time.
Althoughmany studies reported a loss of DAPK1 expression in
human tumors, the molecular bases have not been understood.
In a previous study (23), we reported thatDAPK1 transcription
is repressed by p52 NF-B and histone deacetylases in the Flt3-
ITD subset of acutemyeloid leukemias. Thismechanism does
not appear to hold true in the case of CLL, a genetically and
cytologically distinct disease.
CLL is a progressive B cell malignancy that exhibits hetero-
geneity in its biology, progression, and overall survival of
patients (41). Currently, very few effective therapeutics are
available for treating CLL. Thus, an understanding of the
molecular processes involved in this disease will pave the way
for the development of new drugs. One major reason for cell
survival seems to be defects in IFN-induced autophagy in CLL.
Consistent with this, Beclin1-Thr119 phosphorylation and the
degradation of p62 (SQSTM1) protein were defective inMEC1
cells (Fig. 1). The p62 (SQSTM1) protein, which cargoes oxi-
dized protein aggregates and tethers them to LC3-like proteins,
is also degraded during autophagy (21). In DAPK1-deficient
cells, p62 accumulated, indicating an abrogation of autophagy.
The resultant rise in p62 levels further increases oxidative stress
and DNA instability (42, 43). DAPK1 interacts with MAP1B,
which in turn binds with high affinity to LC3 (1). Both DAPK1
and MAP1B co-localized with -tubulin and actin microfila-
ment (1). Such mechanisms may allow the sliding of the
autophagosomes along the cytoskeletal structures, culminating
in their fusion with lysosomes.
The ER not only serves as an organelle for the synthesis and
export of secreted and cell surface proteins but is also critical
for executing autophagy. Extreme perturbations in ER homeo-
stasis cause cell death (44).Dapk1/MEFs showed protection
against tunicamycin (an ER stress inducer)-induced cell death
(3). These cells not only respond poorly to ER stress but also
exhibit defects in autophagy. How ER stress is coupled to
autophagy is not clear. ATF6 is an ER-resident transcription
factor, whose N-terminal half serves as a transcription factor,
whereas its C-terminal half is a sensor of ER stress (45). In
FIGURE 2.DAPK1 expression is critically dependent on ATF6 and C/EBP-. A and B, Western blotting analyses of the lysates with the indicated antibodies
are shown. Specific genetic alterations of cells and/or treatments (IFN- for 12 h) are also indicated.C, top, immunofluorescence images of DAPI (nuclear stain),
DAPK1 (FITC; green channel), and LC3 (Alexa Fluor 568; red channel). Scale bar, 10 m. Treatment was with IFN- for 12 h. Bottom, quantified relative mean
puncta after background correction. Bars, mean S.D. (error bars) (n 3, 10 independent fields/sample). Relative levels were calculatedwith respect to those
of untreated control values. D, ChIP assays. IFN- treatment was for 12 h. In each case, the soluble chromatin was used as input control. The typical ChIP-PCR
patternswithDAPK1 enhancer-specific primers are shown. E, qPCR analyses of theChIP products. Specific immunoprecipitationproductswere quantified, and
the values were plotted as relative abundance with respect to the NR-IgG control (n 6). F, top panels, Western blotting analyses of lysates with the indicated
antibodies. Cells were treated with IFN- for 12 h. Bottom, histograms show relative intensities of the bands after normalization to those of internal control,
actin.G, qPCR analyses ofDAPK1 transcript. Cells were treatedwith IFN- in the presence of inhibitors (SB202190 (20M), PD98059 (25M), LY294002 (50M),
or DMSO). Inhibitors were added to the cells 30min before IFN treatment for 12 h (n 5). H, qPCR analyses of the ChIP products. ChIP assays were performed
in the B cell line in the presence of the indicated inhibitors. IFN- treatment was for 12 h. In each case, the soluble chromatin was used as input control. PCR
products were quantified, and the values were plotted as relative abundance with respect to the NR-IgG control (n 6).
TABLE 1
Details of CLL samples obtained from patients
Patient
sample Gender Age Ethnicity
yr
A Male 84 Caucasian
B Male 58 Caucasian
C Male 68 Caucasian
D Male 62 Caucasian
E Male 45 African-American
F Female 66 African-American
G Male 72 Caucasian
H Male 39 Caucasian
I Female 60 Caucasian
J Male 41 African-American
K Female 64 African-American
L Male 65 Caucasian
M Female 64 African-American
N Male 56 Asian/Pacific Islander
O Male 62 Caucasian
P Male 62 Caucasian
Q Male 61 Caucasian
R Male 59 African-American
S Male 72 Caucasian
T Male 59 Caucasian
U Male 71 Caucasian
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response to ER stress, ATF6 translocates to the Golgi appara-
tus, where it is cleaved by resident proteases S1P and S2P. This
process releases the active transcription factor part from the
C-terminal portion. The former enters the nucleus and turns on
the expression of specific genes (46). We have recently identi-
fied a unique pathway in which IFN- stimulated proteolytic
activation of ATF6- and ERK1/2-induced phosphorylation
on C/EBP- converge to up-regulate Dapk1 in MEFs (10,
15). In the present study, we show that this pathway is defec-
tive in CLL. C/EBP- and ATF6 binding to the DAPK1 pro-
moter upon IFN treatment was found only in the control B
cell line and not in the CLL cell line. Specifically, IFN-in-
duced phosphorylation of C/EBP- Thr235 was absent in the
CLL cell line (Fig. 2).We demonstrated earlier that this site is
a classic target for ERK1/2 enzymes. Consistent with this,
inhibition of ERK1/2 decreased IFN--inducedC/EBP--de-
pendent DAPK1 expression in the control B cell line. Simi-
larly, we have recently reported that p38 MAPK-induced
phosphorylation of ATF6 is required before its cleavage in
the Golgi apparatus (15, 16). Indeed, blockade of p38 MAPK
also inhibited IFN-induced DAPK1 expression.
The pathological relevance of this pathway was further
supported by the observation that low levels of either ATF6
or CEBPB correspond to low DAPK1 expression in primary
CLLs (Fig. 3). More importantly, restoration of the missing
factors into primary tumors reinstated DAPK1 expression
and autophagy (Fig. 5). It is likely that defects occur at mul-
tiple levels in the ATF6C/EBP--dependent DAPK1 path-
way in CLL. In the cell line model, C/EBP- phosphorylation
was found to be defective. In the primary CLLs analyzed
FIGURE 3. Loss of DAPK1 expression correlates with those of ATF6 and CEBPB in primary CLL. A and B, RNA was isolated from CLL patient samples as
described under “Experimental Procedures,” and qPCR analyses with the transcript-specific primers (listed in Table 2) were performed. The dot plots show
relative abundance of the indicated transcripts (normalized to the internal control, ribosomal protein L32). Transcript abundance was calculated on the basis
of threshold cycle values. Eachdot shows themeanof each sample.n5 for PBL;n21 for CLL.C, plot showing relative abundanceof the indicated transcripts
in each CLL sample.D, qPCR analyses of the ChIP products. ChIP assays were performed in CLL samples in the presence and absence of IFN-. IFN- treatment
was for 12 h. In each case, specific immunoprecipitation products were quantified, and the values were plotted as relative abundance with respect to the
NR-IgG control (n 6). Error bars, S.D.
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here, we noted a decline in ATF6 and/or C/EBP- levels.
This does not mean that C/EBP- phosphorylation is irrele-
vant to primary CLL. Like many cancers, CLL is a heteroge-
neous disease. Thus, it is important to examine these find-
ings in a larger cohort of patient samples before arriving at
such an inference.
FIGURE 4. Critical role for ATF6/C/EBP- in driving IFN-induced autophagy in CLL. A, top panels, immunofluorescence images of LC3 (FITC; green channel)
andC/EBP-ATF6 (AlexaFluor 568; red channel). DAPIwasused to stain thenucleus (blue channel). Scale bar, 15m.Representative images fromthreedifferent
patient samples are shown. Bottom, histograms show quantified fluorescence (Alexa Fluor 568 (red) or FITC (green) from three different patient samples after
background correction. Bars, mean S.D. of 10 independent fields per sample). B and C, top panels, Western blotting analyses of lysates with the indicated
antibodies. Specific patient samples and treatments alongwith their controls are indicated: IFN- for 12 h, flavopiridol for 4 h, and chlorambucil for 4 h. Bottom,
histograms showthe relative intensities of thebandsafter normalization toactin control.D, viability of the cell lines after specific treatments (IFN-, flavopiridol,
or chlorambucil) at the indicated time points. Experiments were performed in triplicate, and results are reported as mean S.D. (error bars).
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ATF6, a major mediator of ER stress-driven transcription,
binds to the ER stress response element in the target gene pro-
moters, such as BiP (47). Additionally, upon ER stress, transla-
tional shutdown leads to selective translation of ATF4 mRNA
(48). Our data show that the ER stress response genes HSPA5
andATF4were significantly low in these CLL samples, indicat-
ing a poor ER stress response (Fig. 3). Defective autophagy
caused a poorer anti-tumor response. Consistent with these
reports, increase in LC3-II levels, p62 degradation, and
DAPK1-dependent Beclin1 phosphorylation did not occur in
primary CLL samples in response to IFN-, flavopiridol, or
chlorambucil (Fig. 4). Importantly, re-expression of C/EBP-
and ATF6 in primary CLL samples resulted in restoration of
IFN-inducedDAPK1 expression and autophagy (Fig. 5). In light
of these observations, we hypothesize that lower levels and/or
aberrations inATF6 andC/EBP- activationmay be prognostic
for a poorer therapeutic response (Fig. 6) in CLL. That said,
more detailed studies with a larger cohort of patients, whose
therapeutic histories have been recorded, are required for arriv-
ing at a firmer conclusion. Such investigations are beyond the
scope of the current study.
As mentioned above, autophagy acts both as a cell survival
and a cell suicide mechanism, depending on the physiological
condition and the type of cell. Cells with high basal autophagy
tend to exhibit reduced sensitivity to chemotherapeutics, which
has been inappropriately dubbed “drug resistance,” a separate
mechanism that actively pumps the drugs out using ABC trans-
porters to minimize cytotoxicity (49). A recent study indicated
that CDK-1/5 inhibition by flavopiridol induced autophagy and
ER stress to block CLL growth (28). CDKs 1 and 5 have been
shown earlier to negatively regulate autophagy (50) via a direct
phosphorylation of Vps34 at its Thr159 residue, which blocked
its interaction with Beclin1. Vps34 is an essential component of
the Ambra1UVRAGBeclin1Vps34Vps15 complex that is
necessary for the formation of autophagophore/omegasome,
the precursor for autophagosome (51).Mahoney et al. (28) sug-
gested that activation of the ER stress via the IRE1-TRAF2-
ASK1-Caspase-4 axis by flavopiridol contributes to CLL death.
We have shown here that DAPK1 induction via ATF6 is critical
for suppressing cell survival. DAPK1 phosphorylation of
Beclin1 is an important step in the execution of growth-sup-
pressive autophagy (36). We have reported recently that
DAPK1 expression is controlled by an ASK1-dependent phos-
phorylation of ATF6, which then allows its proteolytic cleavage
in the Golgi and nuclear migration (15, 16). Thus, the IRE1-
TRAF2-ASK1 and the ASK1-ATF6-DAPK1 axes may comple-
ment each other in promoting cell growth suppression in
response to flavopiridol.
Some studies suggested an important role for microenviron-
ment, where CLL expands within pseudofollicles. Stromal cells,
FIGURE 5. Re-expression of C/EBP- and ATF6 into CLL patient samples
restores autophagy. A and B, specific patient samples were transfected
either with vector alone or C/EBP- or ATF6 expression vectors and were
analyzed by Western blotting with specific antibodies. IFN- treatment was
for 12h.C, top panels, fluorescence signals of nucleus (DAPI;blue channel) and
LC3 (FITC; green channel). Scale bar, 10m; IFN- for 12 h. Bottom, quantified
relative fluorescence of LC3 (FITC; green channel) after background correc-
tion. Bars, mean S.D. (error bars) (10 independent fields/sample).
FIGURE 6. A hypothetical model of IFN-induced DAPK1-driven CLL cell
death. In normal B cells, IFN- activates C/EBP- through ERK1/2-dependent
phosphorylation and ATF6 by proteolytic processing. A C/EBP-ATF6 com-
plex recruits to the DAPK1 enhancer and induces its expression and
autophagy. In CLL, either low expression of these factors (C/EBP- and/or
ATF6) or loss of activation of C/EBP- results in loss of collaboration of
C/EBP- and ATF6, which results in a failure to up-regulate optimal DAPK1
levels for the execution of autophagy.
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vascular endothelial cells, monocyte-derived nurse-like cells,
and Th1 cells have been suggested to promote survival, prolif-
eration, and migration of CLL cells (52–55). A recent study
suggested that Th1-derived IFN- induced cell surface CD38
expression, via the JAK-STAT pathway, and requires the par-
ticipation of transcription factor T-bet (56). CD38 is associated
withCLL cell proliferation. The pathway used for up-regulating
DAPK1 is distinct from the one used for inducing CD38. For
example, DAPK1 expression does not require STAT1. Unlike
CD38, DAPK1 promotes cell death and autophagy. One dis-
tinction between our study and that of Burgler et al. (57) is the
absence of other cell types that create pseudofollicles because
tumor cells used in the present study were derived from B cells
enriched from peripheral blood. Despite these distinctions, our
studies are not at odds with each other; gain and loss of CD38
and DAPK1, respectively, complement each other, in promot-
ing CLL growth. Whether these two events occur simultane-
ously or at different stages of CLL evolution is an interesting
question to be examined. The limited cell numbers obtained
from CLL patients and lack of bone marrow samples from the
same patients currently do not permit us such a rigorous exam-
ination of such issues at this time.
Meanwhile, our results suggest that regulation of autophagy
via ATF6-C/EBP- may be an important contributor to the
suppression of CLL growth. Apart from C/EBP-, ATF6 is also
down-regulated during prostate cancer progression (58). A
missense SNP in ATF6 is associated with the progression of
hepatocellular carcinoma (59). C/EBP- is also down-regulated
in some human hepatocellular carcinomas (60). In sum, our
studies for the first time couple ATF6C/EBP- to a major
tumor suppressor, DAPK1, in CLL.
Experimental Procedures
Cell Lines and Other Reagents—An Epstein-Barr virus-im-
mortalized human B cell line (CHS International Research Ltd.,
Orange, CA) (61) was grown in RPMI 1640 supplemented with
10% fetal bovine serum and 1% antibiotic-antimycotic agents.
This cell line is non-oncogenic and does not exhibit any growth
abnormalities. Because it expresses DAPK1 like normal PBLs,
we used it as a control. MEC1, a CLL cell line (62), was cultured
in McCoy’s 5A medium. The ERK pathway inhibitor PD98059
and the PI3K inhibitor LY294002 were from EMD Millipore
(Billerica, MA). p38 MAPK inhibitor SB202190, chlorambucil,
and flavopiridol were from Sigma-Aldrich. Human IFN- was
from PBL Inc. (Piscataway, NJ). Antibodies specific for DAPK1
were from Sigma-Aldrich. Rabbit antibodies against the phos-
pho-Thr235 form of C/EBP- were provided by Peter Johnson
(NCI, National Institutes of Health, Frederick, MD). Rabbit
antibodies against ATF6 and C/EBP- were from Santa Cruz
Biotechnology, Inc. (Dallas, TX).
Primary CLL Samples—Blood samples were collected from
subjects diagnosed with CLL, after informed consent, at the
University of Maryland Greenebaum Cancer Center (Balti-
more, MD) under an institutional review board-approved
protocol. These patients included Caucasians and African-
Americans of both sexes. The Accuspin system-HIS-
TOPAQUE-1077 (Sigma-Aldrich) was used for separating leu-
kocytes from whole blood, and B cells were isolated using a
pan-B cell enrichment kit (Stemcell Technologies Inc., Van-
couver, Canada). In brief, undesired cells were removed with
the use of tetrameric antibody complexes recognizing CD2,
CD3, CD14, CD16, CD36, CD42b, CD56, CD66b, CD123, gly-
cophorin A, and dextran-coated magnetic particles. Finally,
CD5CD19, CD20, and CD23 positive cells (98% pure) were
separated from the remaining population using specific anti-
bodies and used for further analysis as described below. PBLs
from normal volunteer blood were used as the control for com-
paring the data from CLL patients.
qPCR—Transcript levels of specific genes were determined
using specific primers as in our earlier studies (10, 16). Addi-
tional primers are described in Table 2. The ribosomal protein
L32 (RPL32) mRNA was used as an internal control. Relative
transcript abundance was calculated using the Ct method.
All reactions were performed in triplicates, and each experi-
mentwas repeatedwith at least three independent preparations
of RNA.
ChIP Assays—ChIP assays were performed using a com-
mercially available kit (Millipore, Billerica, MA) (10, 16). The
“ChIPed” DNA was quantified using qPCR, with primers
specific for the DAPK1 promoter (40). DNA from total sol-
uble chromatin was used as a template for PCR for determin-
ing input levels. Five micrograms of antibody was used for
ChIPs with either an NR-IgG or specific IgG. No IgG and
NR-IgG served as negative controls and defined the
baselines.
Western Blotting Analysis—Whole cell extracts were frac-
tionated by loading equal amounts of total protein on SDS-
PAGEand transferred to polyvinylidene difluoridemembranes.
Western blotswere probedwith the indicated primary antibod-
ies (1:1000 dilution) overnight at 4 °C. They were washed and
probed with Alexa Fluor-tagged secondary antibodies
(1:2000 dilution) for 1 h at room temperature. Blots were
imaged using the LI-COR Odyssey infrared imaging system
(10, 16). Mean intensities of the appropriate bands from
three separate blots were quantified using the software pro-
vided by the manufacturer and ImageJ software (National
Institutes of Health). Background intensities were sub-
tracted and normalized to actin levels. Only representative
images are shown. Vertical lines in the blot images indicate
TABLE 2
Gene-specific primers used in qPCR
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that the figure was recomposed from relevant lanes of the
same blots after removing unrelated parts.
RNAi and Overexpression Analysis of DAPK1, C/EBP-, and
ATF6—Lentiviral vectors carrying short hairpin RNAs
(shRNAs) specific for human DAPK1, CEBPB, and ATF6 were
from Open Biosystems, Inc. (Table 3). Virus stocks were pre-
pared as recommended by the supplier and used as described in
our earlier studies (10). Knockdown of the target gene products
was assessed byWestern blotting analyses. For overexpression,
we transfected the indicated cells with expression vectors cod-
ing for either full-length human DAPK1, C/EBP-, or ATF6
(10, 16) usingAmaxaNucleofector technology. To avoid poten-
tial overexpression artifacts, DNA transfection studies were
performed with transgene expression levels corresponding to
endogenous levels.
Immunofluorescence Microscopy—These analyses were con-
ducted as described earlier (15, 16). Anti-LC3 (1:1000), anti-
DAPK1 (1:500), anti-ATF6 (1:500), or anti-C/EBP- (1:1000)
was used as primary antibody, and Alexa Fluor- or FITC-con-
jugated anti-rabbit IgG (1:50) or anti-mouse IgG (1:50) was
used as secondary antibody. Images were captured using a
QICAM digital camera and were processed using Q-Capture
Pro version 5.1 (Q-imaging). Mean intensities of fluorescent
signals were quantified using ImageJ (National Institutes of
Health).
Cell Viability Assay—Cells were plated in 24-well plates at
1 105 cells/well and treated either with IFN- or flavopiridol
or chlorambucil for specific time points. Cell viability wasmea-
sured by adding trypan blue and counting with a Cellometer
Auto T4 counter (Nexcelom Bioscience, Lawrence, MA).
Statistical Analysis—Data were subjected to Student’s t test,
and p	 0.05 was considered significant.
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discussed the results and the interpretations.
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